Halozyme Therapeutics: 3Q Earnings Snapshot

November 6, 2018

SAN DIEGO (AP) _ Halozyme Therapeutics Inc. (HALO) on Tuesday reported a third-quarter loss of $27.9 million, after reporting a profit in the same period a year earlier.

The San Diego-based company said it had a loss of 19 cents per share.

The results exceeded Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 23 cents per share.

The biopharmaceutical company posted revenue of $25.6 million in the period, falling short of Street forecasts. Three analysts surveyed by Zacks expected $30.9 million.

Halozyme Therapeutics expects full-year revenue in the range of $150 million to $160 million.

Halozyme Therapeutics shares have declined 22 percent since the beginning of the year. In the final minutes of trading on Tuesday, shares hit $15.80, a decrease of 7 percent in the last 12 months.


This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on HALO at https://www.zacks.com/ap/HALO

Update hourly